|
| 37943684 | Iterative Causal Forest: A Novel Algorithm for Subgroup Identification. | Am J Epidemiol | 2024 |
| 37758044 | Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. | Am Heart J | 2024 |
| 38071615 | Geriatric Assessment Impairment Profiles and Mortality in Older Adults With Gastrointestinal Cancers: Latent Class Analysis of the CARE Registry. | J Gerontol A Biol Sci Med Sci | 2024 |
| 36124697 | Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial. | Clin Infect Dis | 2023 |
| 38028337 | Case study of semaglutide and cardiovascular outcomes: An application of the C<i>ausal Roadmap</i> to a hybrid design for augmenting an RCT control arm with real-world data. | J Clin Transl Sci | 2023 |
| 37625001 | Felicia Hill-Briggs: A Tireless Worker for Better Outcomes and Social Justice in Diabetes. | Diabetes Care | 2023 |
| 38011528 | A New Partnership: Bringing Novel Aspects of CDC Data to Diabetes Care. | Diabetes Care | 2023 |
| 37900353 | A causal roadmap for generating high-quality real-world evidence. | J Clin Transl Sci | 2023 |
| 37552540 | Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. | JCI Insight | 2023 |
| 38057427 | Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex. | Nat Biomed Eng | 2023 |
| 38033705 | Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2. | J Clin Transl Sci | 2023 |
| 36952610 | Reducing Bias in Academic Publishing: The Diabetes Care Approach. | Diabetes Care | 2023 |
| 37125061 | Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection? A population-level view in the EHR-based RECOVER program. | J Clin Transl Sci | 2023 |
| 37456267 | Site readiness practices for clinical trials - considerations for CTSA hubs. | J Clin Transl Sci | 2023 |
| 37456265 | A framework for assessing clinical trial site readiness. | J Clin Transl Sci | 2023 |
| 37017470 | Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE. | Diabetes Technol Ther | 2023 |
| 36945734 | Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. | Diabetes Obes Metab | 2023 |
| 37385279 | Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. | Lancet | 2023 |
| 37339345 | Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2. | Diabetes Care | 2023 |
| 37335978 | Impact of Continuous Glucose Monitoring Initiation on Emergency Health Services Utilization. | Diabetes Care | 2023 |
| 37302406 | Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. | Lancet Infect Dis | 2023 |
| 37137527 | Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial. | BMJ Open Diabetes Res Care | 2023 |
| 37333243 | Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial. | medRxiv | 2023 |
| 37329282 | Use of comprehensive recruitment strategies in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) multi-center clinical trial. | Clin Trials | 2023 |
| 36480256 | Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes. | Diabetes Technol Ther | 2023 |
| 36548704 | "The Times They Are A-Changin'" at Diabetes Care. | Diabetes Care | 2023 |
| 36470556 | Medically tailored meals for food insecurity and type 2 diabetes: Protocol for the Food as Medicine for Diabetes (FAME-D) trial. | Contemp Clin Trials | 2023 |
| 36845305 | Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT). | J Clin Transl Sci | 2023 |
| 36701596 | The Art of Diabetes Care. | Diabetes Care | 2023 |
| 36383734 | Questionnaire-Based Polyexposure Assessment Outperforms Polygenic Scores for Classification of Type 2 Diabetes in a Multiancestry Cohort. | Diabetes Care | 2023 |
| 34716214 | Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. | Diabetes Care | 2022 |
| 35551293 | A new class of drug in the diabetes toolbox. | Nat Med | 2022 |
| 35801339 | Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. | Diabetes Obes Metab | 2022 |
| 35661378 | Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes. | Diabetes Obes Metab | 2022 |
| 35392460 | Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. | Open Forum Infect Dis | 2022 |
| 35861431 | Antihyperglycemic Medication Use Among U.S. Adults With Hemodialysis-Dependent Kidney Disease and Comorbid Diabetes. | Diabetes Care | 2022 |
| 35386046 | Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). | Drugs Real World Outcomes | 2022 |
| 36597543 | Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up. | medRxiv | 2022 |
| 36482974 | Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection? | medRxiv | 2022 |
| 36148880 | Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Diabetes Care | 2022 |
| 36070710 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. | N Engl J Med | 2022 |
| 36098660 | Effect of SARS-CoV-2 Infection and Infection Severity on Longer-Term Glycemic Control and Weight in People With Type 2 Diabetes. | Diabetes Care | 2022 |
| 36170500 | Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. | N Engl J Med | 2022 |
| 36129996 | Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. | N Engl J Med | 2022 |
| 36129997 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. | N Engl J Med | 2022 |
| 36059915 | Salivary Metabolomics of Well and Poorly Controlled Type 1 and Type 2 Diabetes. | Int J Dent | 2022 |
| 36395143 | Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study. | PLoS One | 2022 |
| 36151309 | Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Diabetologia | 2022 |
| 35132865 | Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. | J Am Heart Assoc | 2022 |
| 35069442 | Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress. | Front Endocrinol (Lausanne) | 2022 |